Biotech Squalane Market

Biotech Squalane Market Outlook (2025 to 2035)

The global biotech squalane market is expected to reach USD 110.6 million by 2035, up from USD 61.2 million in 2025. During the forecast period 2025 to 2035, the industry is projected to expand at a CAGR of 6.1%.

Consumer preference for sustainable and ethically sourced ingredients is driving demand in the biotech squalane market, further reinforced by regulatory pressures. Biotech squalane is valued for its high purity and efficacy, making it a preferred choice in premium cosmetics. Advances in synthetic biology and fermentation technologies now enable large-scale production at competitive costs with consistent quality across batches.

Quick Stats for Biotech Squalane Market

• Industry Value (2025): USD 61.2 Million
• Projected Value (2035): USD 110.6 Million
• Forecast CAGR (2025 to 2035): 6.1%
• Leading Segment (2025): Phyto-derived Squalane (66.7% Market Share)
• Fastest Growing Country (2025-2035): France (6.8% CAGR)
• Top Key Players: Wilshire Tech, Caribbean Natural Products Inc., Kuraray, Enepret Inc., Croda Pharma, Sophim

What are the drivers of the biotech squalane market?

The demand for effective substitutes of shark-derived squalane with more sustainable and ethical solutions could be regarded as one of the most important drivers of the biotech squalane market. Consumers and regulatory bodies alike are notably shunning animal-derived ingredients, and there are additional pressures in that squalane fermentation-derived ingredients represent an ethical and environmental solution that does not sacrifice performance.

The other main factor is the fast-increasing market of cosmetics and the personal care segment, especially premium skincare. Biotech squalane has become appreciated as a high-performing emollient, offering stability and purity, well-suited to moisturizers, serums, sunscreens, and anti-aging products that meet clean beauty trends globally.

The market is also growing because of progress in artificial biology and fermentation technology. These technologies facilitate scalable, low-cost, and highly pure commercial production of squalane, providing a steady supply of a squalane feedstock to pharmaceutical, biotech, and cosmetic uses, and minimizing reliance on sources such as olives/shark liver oil.

What are the regional trends of the biotech squalane market?

The biotech squalane market in North America is on an upward trend due to powerful biotechnology centers, the adoption of pharmaceuticals and sustainable clean beauty industry. Along with the leader, the United States has become the innovation and use leader, with the companies scaling up the fermentation-based production, utilizing it in its cosmetic and vaccine applications.

Europe is a leading market is the sustainability regulation and demand of consumers to have ethical beauty products. France is also a leading place with Givaudan and Sophim being the suppliers of luxury cosmetic brand and promoting extensive use of biotech squalane in the region.

The Asia-Pacific has become the fastest-growing market with China, Japan and South Korea leading in driving keen demand due to booming beauty and skincare industries. The region is further developing biotechnology innovation and bio-manufacturing capacity as the local consumer develops awareness of sustainable and non-cruelty ingredients.

In Latin America, there is an emerging potential, especially in Brazil when sugarcane acts as a major feedstock to fermentation-based squalane. The drivers of the growth include the growing consumer demand to use natural cosmetics and the interest of the global suppliers to enter the region.

What are the challenges and restraining factors of the biotech squalane market?

The high cost involved in the fermentation process poses a challenge to the biotech squalane market. The sustainability and efficiency thereof notwithstanding, such technologies demand a substantial expenditure into research and development as well as infrastructure and scaling, which makes the produced biotech squalane costly in comparison to the traditional approaches to do the same with plant-based alternatives, e.g., squalane of olive-based origin.

The second issue is that there is a lack of awareness and uptake in the emerging markets, which are cost-sensitive. The entry of biotech squalane is hampered by the continued dominance of low-cost substitutes used by many small and midsize cosmetic formulators in developing markets due to their lower cost and potential performance profile.

One of the constraints is the reliance on feedstock supply, particularly sugarcane or other plant-based feedstocks used in fermentation. Variability of production, prices, and land-use pressure of agricultural raw materials on bio-based raw materials inputs can disturb the stability of supply and undermine sustained growth in global markets.

Country-Wise Insights

U.S. biotech squalane market advances through bioeconomy initiatives and fermentation scale-up

Federal bioeconomy development plans, clean energy stimulus, and drug development initiatives are fueling a faster growth in U.S. biotech squalane market as bio-sourced ingredients for topical use are favored over animal-based sources. The pro-sustainable cosmetics and FDA backing of vaccine adjuvants has driven the development of fermentation derived squalane through both consumer passed and healthcare applications.

States with a high concentration of innovation (such as California and Massachusetts) are settling sophisticated fermentation fermenters, GMP-proofed lipid plants, and testbeds for synthetic biology and advanced purification techniques. Industry leaders like Amyris and Croda and biotech startups and university consortia are becoming leaders in precision fermentation, metabolic engineering, and scalable downstream processes.

Bio-process toolkit, microbial strain and quality certification frameworks, standardization would be aligned with US commitments to enhance domestic biomanufacturing capabilities, fast-track commercialization, and eliminate reliance on petrochemicals, or animal-derived components.

Japan biotech squalane market advances through cosmetic innovation and sustainable fermentation practices

A vibrant Japan biotech squalane industry is led by a robust demand core on par with the world-renowned Japanese cosmetics market and within government-supported sustainability systems that stress non-animal ingredient sourcing. Both green chemistry and ethical beauty, and progressive innovation policies have aided the production of fermentation-based squalane as a luxury skincare and drug ingredient.

Tokyo, Osaka, and Kyoto R&D centers are underway, propping metabolism activities, pilot fermentation lines, and testbed purification to support high-purity performance to align with the local regulatory structure. Other corporations like Kuraray, Nikkol Group, and Shiseido are in the production of precision fermentation, bio-based feedstock optimization, and molecular tailoring of the emollients as a way of incorporating into the ultraluxury product line.

International initiatives to address uniformity in manufacturing, packaging and inter-industrial partnerships are in tandem with the Japanese agenda of staying at the forefront of sustainable cosmetic and biotechnology-based materials.

France biotech squalane market advances through luxury cosmetics and circular bioeconomy programs

The squalane market in France is growing at a robust pace, contributed by the luxury cosmetic industry as well as the endeavors of the government that lend weight to sustainability using bio-based raw materials. Increased national regulation on clean beauty and circular economy, combined with the shift toward ethical sourcing of ingredients, has led to the rapid penetration of fermentation-derived squalane into skincare, haircare and pharmaceutical products.

The cluster of innovation in Paris, Lyon, and Marseille is assisting in pilot fermentation facilities, biotech incubators and working R&D activities on high-purity lipids development. Other corporations like Givaudan, Sophim and L'Oréal are incorporating precision fermentation, which involves valorising olive by-products, and sophisticated formulation research to include squalane in their high-end product categories.

Green certification, eco-labeling of packaging materials and academia-industry research collaboration also fit into the mandate of France being a global leader in sustainable beauty and bio-innovation.

Category-Wise Analysis

Phyto-derived squalane market advances through circular bioeconomy and green cosmetics integration

The market for squalane is growing because the international cosmetic and pharmaceutical industries are turning to plant sources to replace products derived from sharks. Regulation encouragement of cruelty-free and eco-labeled formulations has motivated companies to isolate squalane from olive squalane, sugarcane, rice bran and amaranth using eco-friendly valorization strategies.

New markets such as Europe and Asia-Pacific are investing in pilot extraction plants, bio-refinery hubs and sustainable economy projects to upcycle farm waste to produce high-purity emollients. The producers include Sophim, Givaudan, and Clariant, which promote olive byproducts valorization, sugarcane-based fermentation hybrids, and eco certification systems, in integrating the phyto-derived squalane into top-shelf skincare and personal care lines.

The initiatives towards green certifications standardization, enhancement of feedstock and refinement traceability further green sheet and bolster the concept of phyto-derived squalane as a lodestar in the clean beauty and bio-based ingredient industries driven by global sustainability objectives.

Cosmetics & personal care biotech squalane market advances through clean beauty trends and sustainable ingredient adoption

There is a fast-growing requirement in the Cosmetics & personal care squalane market driven by consumer needs in terms of sustainability, cruelty-free, and high-performance formulations. The movement to replace oils (including shark-derived oils) to fermentation-derived or plant-derived squalane has been exacerbated by supportive laws in key markets of the U.S., EU, and Japan.

International beauty centres are pumping funds into research and development facilities, formulated laboratories and certification systems to guarantee certification and high performance in product quality. Major brands like L'Oréal, Shiseido, and Unilever, the biotech firms such as Amyris and Croda, are leading the drive to include precision fermentation, clean packaging, multi-active ingredient integration that can play a bigger role in moisturizers, and serums and sunscreen.

Circular packaging, traceable supply chains, and eco-certification, as well as industry-wide steps to improve clean beauty, add up to the broader clean beauty movement and make biotech squalane a linchpin of future innovation in the cosmetics and personal care industry.

Liquid squalane market advances through premium skincare integration and biotech-driven purity standards

High-purity liquid squalane is in demand across cosmetic, personal care, and pharmaceutical markets as producers focus on using emollients that are high-purity bio-based ingredients with stable sensory performance. The move away to using plant extract or biotech-fermented liquid squalane in serums, moisturizers and topical treatments has been enhanced by regulatory encouragement of cruelty-free and sustainable formulations.

Europe, North America and Asia are investing in state-of-the-art purification, formulation labs and GMP-approved bioreactors in order to provide consistent quality and scale. Manufacturers like Croda, Givaudan and Amyris are bravely entering the game to produce precision fermentation, feedstock modification, and molecular production of liquid squalane to suit high-end cosmetic and dermatological purposes.

Competitive Analysis

Biotech squalane market is a novel industry whose characterising features are its sustainable feedstock, new-fangled fermentation design, and high-fidelity further processing all of which are markers of competitiveness. Leading the list of obstacles is the ease with which manufacturers can produce biotech squalane industrially in quantities considered consistent in terms of purity, traceability, and cost without jeopardising eco-certification or cosmetic standard.

A scalable fermentation platform, robust microbial strain design, and uniformity in bioprocessing toolkits are still crucial to batch-to-batch fidelity, particularly with pharmaceutical-quality / vaccine-adjuvant products.

The maturity stage of fermentation technologies, circular bioeconomy integration, strategic collaborations with cosmetics giants, pharmaceutical companies and bio-refinery operators, shapes market positioning. Versatile multi-application zones across luxury cosmetics, personal care, and nutraceuticals and adjuvants of healthcare applications enhance market versatility.

Key players in the biotech squalene industry are Wilshire Tech, Caribbean Natural Products Inc., Kuraray, Enepret Inc., Croda Pharma, Sophim, and others.

Recent Developments

• In April 2025, Biotechbeauty launches a microbiome-friendly makeup line, bridging biotech-powered skincare & high-performance color.
• In November 2023, Evonik launches GMP-quality plant-based squalene

Fact.MR has provided detailed information about the price points of key manufacturers of the Biotech Squalane Market positioned across regions, sales growth, production capacity, and speculative technological expansion, in the recently published report.

Methodology and Industry Tracking Approach

A team of more than 9,800 experts directly involved in biotechnology-based ingredients, fermentation design, sustainable lipid chemistry as well as cosmetic formulation, pharmaceutical integration and regulatory compliance in the production of next generation bio-based emollients participated in targeted interviews to develop this 2025 Global Biotech Squalane Report. Participants were senior fermentation technologists, microbial strain developers, R&D leaders at cosmetic and pharmaceutical companies, sourcing and purchasing leaders at personal care and medical OEMs, sustainability and compliance experts, bio-refiners, packaging disruptors and other biotech start-ups.

The design of the research was horizontal since a series of formulated questions were used in the research between September 2024 and July 2025. In this approach, scalability, purity, and sustainability overview on biotechnical production of squalane were conducted, as well as the application thereof in high-performance skincare, haircare, and pharmaceutical products.

With Fact.MR monitoring consumer behavior, product efficacy, industry trends, and market opportunities since 2018, this report is becoming an authoritative source of information that stakeholders can rely on.